Peer-reviewed veterinary case report
Parathyroid hormone receptor 1 predicts survival in dogs with bone
By Al-Khan, Awf A et al.·Published in Scientific reports·2020·RMIT University, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Parathyroid hormone receptor 1 (PTHR1) is a prognostic indicator in canine osteosarcoma.
- Species:
- dog
Plain-English summary
A study found that dogs with osteosarcoma (a type of bone cancer) often have a protein called parathyroid hormone receptor 1 (PTHR1) in their tumors. In 50 dogs diagnosed with this cancer, those with higher levels of PTHR1 had shorter survival times compared to those with lower levels. This suggests that measuring PTHR1 could help veterinarians predict how well a dog might do after being diagnosed with osteosarcoma. While the presence of another protein, PTHrP, did not show a link to survival, PTHR1 could be an important factor in understanding the prognosis for dogs with this condition.
People also search for: dog osteosarcoma prognosis · PTHR1 in dog cancer · osteosarcoma treatment for dogs
Abstract
Osteosarcoma (OS) is the most common malignant primary bone tumour in humans and dogs. Several studies have established the vital role of parathyroid hormone-related protein (PTHrP) and its receptor (PTHR1) in bone formation and remodeling. In addition, these molecules play a role in the progression and metastasis of many human tumour types. This study investigated the expression of PTHR1 and PTHrP in canine OS tissues and assessed their prognostic value. Formalin-fixed, paraffin-embedded tissue samples from 50 dogs diagnosed with primary OS were immunolabeled with antibodies specific for PTHR1 and PTHrP. The immunostaining intensity of tumours from patients with OS was correlated with survival time. Both PTHR1 and PTHrP were detected in all OS samples (n = 50). Dogs with OS tumours showing high immunostaining intensity for PTHR1 (n = 36) had significantly shorter survival times (p = 0.028, Log Rank; p = 0.04, Cox regression) when compared with OS that had low immunostaining intensity for PTHR1 (n = 14).PTHrP immunostaining intensity did not correlate with survival time (p > 0.05). The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic indicator in canine OS.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32005896/